ZBIO | ProShares UltraPro Short Nasdaq Biotechnology ETF Overview

(Stock Exchange: NASDAQ)

Day's Range	9.31 - 10.38
52 Week Range	8.33 - 26.25
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	2,851,839
Average Volume	233,606
Shares Outstanding	41,791,040
Inception Date	2024-09-13

Assets	2,514,455
Asset Class	Equity
Expense Ratio	N/A
P/E Ratio	-3.24
EPS	-3.09
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

*Chart delayed

Watching at ZBIO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ZBIO Technicals page.